Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
86,510 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| May 14, 2026 | HealthPartners | Oncology - cemiplimab-rwlc (Libtayo) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-221633 | New policy |
|---|
| May 14, 2026 | HealthPartners | Oncology - caplacizumab-yhdp (Cablivi)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-210231 | New policy |
|---|
| May 14, 2026 | HealthPartners | Oncology - brentuximab vedotin (Adcetris) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-231701 | New policy |
|---|
| May 14, 2026 | HealthPartners | Oncology - blinatumomab (Blincyto)PayerPolicy · HEALTHPARTNERS-CC-AENTRY-045816 | New policy |
|---|
| May 14, 2026 | HealthPartners | Oncology - bevacizumab (Avastin, Mvasi, Zirabev, Alymsys, Vegzelma, Jobevne)PayerPolicy · HEALTHPARTNERS-CC-AENTRY-045654 | New policy |
|---|
| May 14, 2026 | HealthPartners | Oncology - belantamab (Blenrep) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-233951 | New policy |
|---|
| May 14, 2026 | HealthPartners | Oncology - avelumab (Bavencio) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-203024 | New policy |
|---|
| May 14, 2026 | HealthPartners | Oncology - atezolizumab (Tecentriq) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-233952 | New policy |
|---|
| May 14, 2026 | HealthPartners | Oncology - asparaginase Erwinia chryanthemi (Erwinaze) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-231702 | New policy |
|---|
| May 14, 2026 | HealthPartners | Oncology - ado-trastuzumab emtansine (Kadcyla), pertuzumab (Perjeta), trastuzumab (Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera), and trastuzumab and hyaluronidase-oysk (Herceptin Hylecta) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-227137 | New policy |
|---|
| May 14, 2026 | HealthPartners | Oncology - ado-trastuzumab emtansine (Kadcyla), fam-trastuzumab deruxtecan-nxki (Enhertu), pertuzumab (Perjeta)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-203715 | New policy |
|---|
| May 14, 2026 | HealthPartners | Onasemnogene abeparvovec-xioi (Zolgensma) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-221637 | New policy |
|---|
| May 14, 2026 | HealthPartners | Omadacycline (Nuzyra) – Minnesota Healthcare ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-217831 | New policy |
|---|
| May 14, 2026 | HealthPartners | Olipudase alfa-rpcp (Xenpozyme)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-257855 | New policy |
|---|
| May 14, 2026 | HealthPartners | Ocular complement inhibitorsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-260879 | New policy |
|---|
| May 14, 2026 | HealthPartners | Ocular anti-VEGF medicationsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-223233 | New policy |
|---|
| May 14, 2026 | HealthPartners | Ocrelizumab (Ocrevus) and ocrelizumab hya-ocsq (Ocrevus Zunovo) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-194059 | New policy |
|---|
| May 14, 2026 | HealthPartners | Ocrelizumab (Ocrevus) and ocrelizumab hya-ocsq (Ocrevus Zunovo)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-193159 | New policy |
|---|
| May 14, 2026 | HealthPartners | Oral and enteral nutrition - Iowa, North Dakota, South Dakota, and WisconsinPayerPolicy · HEALTHPARTNERS-CC-ENTRY-183853 | New policy |
|---|
| May 14, 2026 | HealthPartners | Nutritional support - Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046323 | New policy |
|---|
| May 14, 2026 | HealthPartners | Oral and enteral nutrition - MinnesotaPayerPolicy · HEALTHPARTNERS-CC-ENTRY-279618 | New policy |
|---|
| May 14, 2026 | HealthPartners | Nusinersen (Spinraza)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-191273 | New policy |
|---|
| May 14, 2026 | HealthPartners | Neuromuscular electrical stimulation (NMES) and functional electrical stimulation (FES)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-206035 | New policy |
|---|
| May 14, 2026 | HealthPartners | Neonatal Fc receptor antagonists (Vyvgart, Vyvgart Hytrulo, Rystiggo, Imaavy)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-252184 | New policy |
|---|
| May 14, 2026 | HealthPartners | Natalizumab (Tysabri, Tyruko) - Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-187829 | New policy |
|---|
| May 14, 2026 | HealthPartners | Natalizumab (Tysabri, Tyruko)PayerPolicy · HEALTHPARTNERS-CC-AENTRY-046241 | New policy |
|---|
| May 14, 2026 | HealthPartners | Mucopolysaccharidoses (MPS) drug therapy - Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-187828 | New policy |
|---|
| May 14, 2026 | HealthPartners | Mucopolysaccharidoses (MPS) drug therapyPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046050 | New policy |
|---|
| May 14, 2026 | HealthPartners | Medications for risk reduction of primary breast cancer in womenPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046044 | New policy |
|---|
| May 14, 2026 | HealthPartners | Medication therapy disease management programPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046043 | New policy |
|---|
| May 14, 2026 | HealthPartners | Medically necessary/ medical necessityPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046042 | New policy |
|---|
| May 14, 2026 | HealthPartners | Medical injectable medication quantity and frequency limitation coveragePayerPolicy · HEALTHPARTNERS-CC-ENTRY-222431 | New policy |
|---|
| May 14, 2026 | HealthPartners | Lyme disease - antibiotic treatmentPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046035 | New policy |
|---|
| May 14, 2026 | HealthPartners | Oncology - lutetium Lu 177 dotatate (Lutathera)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-221636 | New policy |
|---|
| May 14, 2026 | HealthPartners | Lumasiran (Oxlumo)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-234243 | New policy |
|---|
| May 14, 2026 | HealthPartners | Lefamulin (Xenleta) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-227134 | New policy |
|---|
| May 14, 2026 | HealthPartners | Laser treatment for skin conditionsPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046029 | New policy |
|---|
| May 14, 2026 | HealthPartners | Ketamine infusionPayerPolicy · HEALTHPARTNERS-CC-ENTRY-232309 | New policy |
|---|
| May 14, 2026 | HealthPartners | Investigational spine proceduresPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046448 | New policy |
|---|
| May 14, 2026 | HealthPartners | Investigational services - list of non-covered servicesPayerPolicy · HEALTHPARTNERS-CC-AENTRY-046292 | New policy |
|---|
| May 14, 2026 | HealthPartners | Investigational servicesPayerPolicy · HEALTHPARTNERS-CC-ENTRY-182851 | New policy |
|---|
| May 14, 2026 | HealthPartners | Intraosseous radiofrequency ablation of the basivertebral nervePayerPolicy · HEALTHPARTNERS-CC-ENTRY-274114 | New policy |
|---|
| May 14, 2026 | HealthPartners | Intra-articular hyaluronan (Viscosupplementation)PayerPolicy · HEALTHPARTNERS-CC-AENTRY-046265 | New policy |
|---|
| May 14, 2026 | HealthPartners | Intensity modulated radiation therapy (IMRT)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-290173 | New policy |
|---|
| May 14, 2026 | HealthPartners | Inpatient carePayerPolicy · HEALTHPARTNERS-CC-AENTRY-046138 | New policy |
|---|
| May 14, 2026 | HealthPartners | Infectious disease testing: vector-bornePayerPolicy · HEALTHPARTNERS-CC-ENTRY-282393 | New policy |
|---|
| May 14, 2026 | HealthPartners | Infectious disease testing: screening and preventionPayerPolicy · HEALTHPARTNERS-CC-ENTRY-282391 | New policy |
|---|
| May 14, 2026 | HealthPartners | Infectious disease testing: respiratoryPayerPolicy · HEALTHPARTNERS-CC-ENTRY-282610 | New policy |
|---|
| May 14, 2026 | HealthPartners | Infectious disease testing: multisystemPayerPolicy · HEALTHPARTNERS-CC-ENTRY-282392 | New policy |
|---|
| May 14, 2026 | HealthPartners | Infectious disease testing: genitourinaryPayerPolicy · HEALTHPARTNERS-CC-ENTRY-282389 | New policy |
|---|